US6495550B2
(en)
*
|
1999-08-04 |
2002-12-17 |
Icagen, Inc. |
Pyridine-substituted benzanilides as potassium ion channel openers
|
CA2378241A1
(en)
|
1999-08-04 |
2001-02-15 |
Icagen, Inc. |
Benzanilides as potassium channel openers
|
EA008778B1
(ru)
*
|
2003-02-26 |
2007-08-31 |
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг |
Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств
|
US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
DE102004029784A1
(de)
*
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004033670A1
(de)
*
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
|
US20060058311A1
(en)
*
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
US20060074088A1
(en)
*
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
US7728134B2
(en)
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
US20060035903A1
(en)
*
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
EP1630163A1
(de)
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
EP1632493A1
(de)
*
|
2004-08-25 |
2006-03-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
CA2578560A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones, method for the production thereof, and use thereof as a medicament
|
DE102004058337A1
(de)
*
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
|
JP2009503014A
(ja)
*
|
2005-08-03 |
2009-01-29 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
呼吸器系疾患の治療におけるジヒドロプテリジノン
|
US7439358B2
(en)
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
DE602007008837D1
(de)
|
2006-02-14 |
2010-10-14 |
Vertex Pharma |
Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
|
WO2007135374A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Astrazeneca Ab |
Dihydropteridine compounds as anti proliferative agents
|
TW200808325A
(en)
*
|
2006-07-06 |
2008-02-16 |
Astrazeneca Ab |
Novel compounds
|
WO2008009909A1
(en)
*
|
2006-07-17 |
2008-01-24 |
Astrazeneca Ab |
Pteridimones as modulators of polo-like kinase
|
WO2008040951A1
(en)
*
|
2006-10-03 |
2008-04-10 |
Astrazeneca Ab |
Compounds
|
NZ576278A
(en)
*
|
2006-10-19 |
2011-12-22 |
Signal Pharm Llc |
Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
|
EP1953163A1
(en)
*
|
2007-02-01 |
2008-08-06 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Pteridinone derivatives as PI3-kinases inhibitors
|
KR101157848B1
(ko)
*
|
2007-03-22 |
2012-07-11 |
다케다 야쿠힌 고교 가부시키가이샤 |
Plk1 저해제로서 유용한 치환된 피리미도디아제핀
|
WO2008157235A1
(en)
*
|
2007-06-13 |
2008-12-24 |
University Of Virginia Patent Foundation |
Rsk inhibitors as anti-septicemia agents
|
US8329695B2
(en)
|
2007-08-03 |
2012-12-11 |
Boehringer Ingelheim International Gmbh |
Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
|
CA2695753A1
(en)
*
|
2007-08-15 |
2009-02-19 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as protein kinases inhibitors
|
WO2009042711A1
(en)
|
2007-09-25 |
2009-04-02 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
EP2215091B1
(en)
*
|
2007-12-04 |
2016-03-30 |
Nerviano Medical Sciences S.r.l. |
Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
|
JP5593234B2
(ja)
|
2008-03-11 |
2014-09-17 |
ユニバーシティー ヘルス ネットワーク |
ニューロペプチドy5r(npy5r)アンタゴニストを使用して癌を治療する方法
|
EP2100894A1
(en)
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
GB0807452D0
(en)
*
|
2008-04-24 |
2008-05-28 |
Chroma Therapeutics Ltd |
PLK inhibitors
|
US8093043B2
(en)
|
2008-06-04 |
2012-01-10 |
New York University |
β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
|
EP2303889A1
(en)
|
2008-06-18 |
2011-04-06 |
F. Hoffmann-La Roche AG |
Halo-substituted pyrimidodiazepines as plkl inhibitors
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
KR101787309B1
(ko)
|
2008-12-09 |
2017-10-18 |
길리애드 사이언시즈, 인코포레이티드 |
톨-유사 수용체의 조절제
|
ES2661850T3
(es)
|
2009-09-14 |
2018-04-04 |
Gilead Sciences, Inc. |
Moduladores de receptores del tipo toll
|
CN102020643A
(zh)
*
|
2009-09-22 |
2011-04-20 |
上海恒瑞医药有限公司 |
二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
|
AU2010298190A1
(en)
|
2009-09-25 |
2012-05-03 |
Vertex Pharmaceuticals Incorporated |
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
|
JP2013505927A
(ja)
|
2009-09-25 |
2013-02-21 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼ阻害剤として有用なピリミジン誘導体の調製方法
|
EP3091021B1
(en)
|
2009-10-26 |
2019-08-28 |
Signal Pharmaceuticals, LLC |
Methods of synthesis and purification of heteroaryl compounds
|
EP2325185A1
(en)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk inhibitor
|
AU2010336509A1
(en)
|
2009-12-23 |
2012-07-19 |
Elan Pharmaceuticals, Inc |
Pteridinones as inhibitors of polo-like kinase
|
EP2536725B1
(en)
|
2010-02-17 |
2015-10-28 |
Boehringer Ingelheim International GmbH |
Dihydropteridinones, method for production and use thereof
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
US9370535B2
(en)
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
TWI708605B
(zh)
|
2011-10-19 |
2020-11-01 |
標誌製藥公司 |
以tor激酶抑制劑治療癌症
|
US9051269B2
(en)
|
2011-11-18 |
2015-06-09 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
WO2013075083A1
(en)
|
2011-11-18 |
2013-05-23 |
Constellation Pharmaceuticals |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
EA026390B1
(ru)
|
2011-12-02 |
2017-04-28 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ 7-(6-(2-ГИДРОКСИПРОПАН-2-ИЛ)ПИРИДИН-3-ИЛ)-1-((ТРАНС)-4-МЕТОКСИЦИКЛОГЕКСИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА, ИХ ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
CA2862289C
(en)
|
2012-02-10 |
2019-11-26 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
US8865716B2
(en)
|
2012-02-23 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones II
|
US9006226B2
(en)
|
2012-02-23 |
2015-04-14 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones I
|
EP2817029B1
(en)
|
2012-02-24 |
2019-07-10 |
Signal Pharmaceuticals, LLC |
Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
US9346812B2
(en)
|
2013-01-16 |
2016-05-24 |
Signal Pharmaceuticals, Llc |
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
|
JP6052527B2
(ja)
*
|
2013-02-21 |
2016-12-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ジヒドロプテリジノンi
|
JP6072308B2
(ja)
*
|
2013-02-21 |
2017-02-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ジヒドロプテリジノンii
|
EP2970305B1
(en)
|
2013-03-15 |
2017-02-22 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
CA2908830C
(en)
|
2013-04-17 |
2021-12-07 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
NZ629230A
(en)
|
2013-04-17 |
2017-05-26 |
Signal Pharm Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
EP2986321A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
|
NZ629332A
(en)
|
2013-04-17 |
2017-05-26 |
Signal Pharm Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
AU2014253978B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer
|
MX2015014455A
(es)
|
2013-04-17 |
2016-07-21 |
Signal Pharm Llc |
Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
|
CA2908957C
(en)
|
2013-04-17 |
2021-05-18 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
|
JP6401250B2
(ja)
|
2013-05-29 |
2018-10-10 |
シグナル ファーマシューティカルズ,エルエルシー |
7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((trans)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン、その固体形態の医薬組成物、及びその使用方法
|
WO2015004075A1
(de)
*
|
2013-07-09 |
2015-01-15 |
Bayer Pharma Aktiengesellschaft |
Modifizierte bet-proteininhibitorische dihydrochinoxalinone und dihydropyridopyrazinone
|
BR112016001457A2
(pt)
|
2013-07-25 |
2017-08-29 |
Dana Farber Cancer Inst Inc |
Inibidores de fatores de transcrição e usos dos mesmos
|
US20150031699A1
(en)
|
2013-07-26 |
2015-01-29 |
Boehringer Ingelheim International Gmbh |
Treatment of myelodysplastic syndrome
|
EP3033334A1
(en)
|
2013-08-15 |
2016-06-22 |
Constellation Pharmaceuticals, Inc. |
Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
|
CN103664845B
(zh)
*
|
2013-12-27 |
2016-02-10 |
湖南欧亚生物有限公司 |
一种Plk激酶抑制剂药物中间体7-氨基-2,3-二氢苯并呋喃-4-甲酸的制备方法
|
JP2017504653A
(ja)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
ジアミノピリミジンベンゼンスルホン誘導体およびその使用
|
JP2017504651A
(ja)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
ジアゼパン誘導体の使用
|
WO2015160882A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
US9737535B2
(en)
|
2014-04-16 |
2017-08-22 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
|
WO2015160880A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2015193228A1
(de)
*
|
2014-06-19 |
2015-12-23 |
Bayer Pharma Aktiengesellschaft |
Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
|
WO2015193229A1
(de)
*
|
2014-06-19 |
2015-12-23 |
Bayer Pharma Aktiengesellschaft |
Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
|
US11116774B2
(en)
|
2014-07-11 |
2021-09-14 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of HIV
|
US9623028B2
(en)
|
2014-07-14 |
2017-04-18 |
Signal Pharmaceuticals, Llc |
Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
WO2016022902A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
EA201790369A1
(ru)
|
2014-09-16 |
2017-10-31 |
Джилид Сайэнс, Инк. |
Твердые формы модулятора толл-подобного рецептора
|
EA201790373A1
(ru)
|
2014-09-16 |
2017-08-31 |
Джилид Сайэнс, Инк. |
Способы получения модуляторов toll-подобных рецепторов
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
WO2016105518A1
(en)
*
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
|
WO2017040190A1
(en)
|
2015-08-28 |
2017-03-09 |
Constellation Pharmaceuticals, Inc. |
Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
|
RU2750164C2
(ru)
|
2015-09-11 |
2021-06-22 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Цианотиенотриазолодиазепины и пути их применения
|
KR20180051576A
(ko)
|
2015-09-11 |
2018-05-16 |
다나-파버 캔서 인스티튜트 인크. |
아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
|
WO2017091673A2
(en)
|
2015-11-25 |
2017-06-01 |
Dana-Farber Cancer Institute, Inc. |
Bivalent bromodomain inhibtors and uses thereof
|
DE102017005089A1
(de)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
|
DE102017005091A1
(de)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
|
EP3529242A1
(en)
|
2016-10-19 |
2019-08-28 |
Constellation Pharmaceuticals, Inc. |
Synthesis of inhibitors of ezh2
|
BR112019027402A2
(pt)
|
2017-06-22 |
2020-07-07 |
Celgene Corporation |
tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
|
CA3080941A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Dana-Farber Cancer Institute, Inc. |
Nek inhibitors and methods of use
|
CA3097774A1
(en)
*
|
2018-04-24 |
2019-10-31 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
CN108610343A
(zh)
*
|
2018-06-12 |
2018-10-02 |
杨文思 |
一种用于治疗癌症的表皮生长因子受体抑制剂及其合成方法
|
WO2020033823A1
(en)
*
|
2018-08-10 |
2020-02-13 |
Yale University |
Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
|
CN111039944B
(zh)
*
|
2018-10-12 |
2021-11-23 |
中国科学院合肥物质科学研究院 |
Mst1激酶抑制剂及其用途
|
CN113637017B
(zh)
*
|
2021-08-12 |
2024-03-26 |
中国药科大学 |
含二氢喋呤结构的化合物及其制备方法与用途
|